Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2) : a randomised, parallel group, open-label trial

Muir, K W, Ford, G A, Ford, I, Wardlaw, J M, McConnachie, A, Greenlaw, N, Mair, G, Sprigg, N, Price, C I, MacLeod, M J, Dima, S, Venter, M, Zhang, L, O’Brien, E, Sanyal, R, Reid, J, Sztriha, L K, Haider, S, Whiteley, W N, Kennedy, J, Perry, R, Lakshmanan, S, Chakrabarti, A, Hassan, A, Marigold, R, Raghunathan, S, Sims, D, Bhandari, M, Wiggam, I, Rashed, K, Douglass, C & ATTEST-2 Investigators 2024, 'Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2) : a randomised, parallel group, open-label trial', The Lancet neurology, vol. 23, no. 11, pp. 1087-1096. https://doi.org/10.1016/S1474-4422(24)00377-6